Verve Therapeutics, Inc. (VERV) has an overall financial health rating of C with a composite score of 0 out of 5.
This suggests the company faces some financial challenges worth monitoring. Rating as of 2025-07-24.
| Date | Rating | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2025-07-24 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2025-07-23 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2025-07-22 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2025-07-21 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2025-07-18 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2025-07-17 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2025-07-16 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2025-07-15 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2025-07-14 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2025-07-11 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2025-07-10 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2025-07-09 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 |
